Last reviewed · How we verify
Ropivacaine 0.35%
Ropivacaine 0.35%, marketed by the University of Texas Southwestern Medical Center, is an established anesthetic with a key composition patent expiring in 2028. Its primary strength lies in its well-established market presence and long-term use in clinical settings. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Ropivacaine 0.35% |
|---|---|
| Also known as | Ropivacaine |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Quadratus Lumborum Block vs Erector Spinal Block for Post Abdomen Surgery Analgesia (NA)
- ESP Block Versus Wound Infiltration for Laminectomy (NA)
- Lidocaine Versus ESP - After Bariatric Surgery (NA)
- Sternotomy PIFB Block in Open Heart Surgery (NA)
- Erector Spinae Plane Block Versus Paravertebral Block for Analgesia After Cardiac Surgery (PEPS) (NA)
- Effect of Dexmedetomidine As Adjuvant to Ropivacaine for Brachial Plexus Block (NA)
- Comparing Fascia Iliaca Compartment Block and Pericapsular Nerve Group Block for Hip Fracture Pain Control (NA)
- Regional Anesthesia for Totally Awake Upper Limb Surgery in PEDiatric Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ropivacaine 0.35% CI brief — competitive landscape report
- Ropivacaine 0.35% updates RSS · CI watch RSS
- University of Texas Southwestern Medical Center portfolio CI